Trial Profile

Serplulimab Combined With NabPE for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast Cancer- A Single-arm, Multicenter, Phase 2 Clinical Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Serplulimab (Primary) ; Epirubicin; Paclitaxel
Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use

04 Jun 2025 Status changed from recruiting to active, no longer recruiting.
31 Jan 2025 Planned End Date changed from 30 Dec 2025 to 30 Dec 2028.
31 Jan 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com